FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Shanmugam Muthusamy					2. Issuer Name <b>and</b> Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ ANIP ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)    Image: Director   10% Owner   10% Owne				
(Last) (First) (Middle) C/O ANI PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/17/2024								Officer (give title below)  Other (specify below)  HEAD OF R&D, COO-NOVITIUM OPS			ow)		
210 MAI	N STREET	T WEST			4. If /	Amend	ment,	Date	of Origin	al File	ed (Month/Da	y/Year)		Indiv	idual or	Joint/Group	Filing (Che	ck Applicable
(Street)	Street) BAUDETTE MN 56623												Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(City) (State) (Zip)			Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - No	n-Deriva	<u> </u>						sposed of							
1. Title of Security (Instr. 3) 2. Transa Date			2. Transacti	ion	2A. De Execu if any	2A. Deemed Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired Disposed Of (D) (Instr.		ed (A) or	5. Amo 4 and 5) Securi Benefi Owned		ount of ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect ct Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Report Transa (Instr.	ed ction(s) 3 and 4)		(Instr. 4)
Common	Stock														68	8,652	D	
Common	Stock			06/17/20	024				S <sup>(1)</sup>		7,946	D	\$61.4	1(2)	72	4,674	I	Held by Esjay LLC <sup>(3)</sup>
Common	Stock			06/18/20	024				S <sup>(1)</sup>		10,607	D	\$60.7	6(4)	71	4,067	I	Held by Esjay LLC <sup>(3)</sup>
Common	Stock			06/20/20	024				S <sup>(1)</sup>		11,447	D	\$59.8	6(5)	70	2,620	I	Held by Esjay LLC <sup>(3)</sup>
Common	Stock														5	,000	I	Held by SS Pharma LLC <sup>(6)</sup>
		Tal	ble II								oosed of, convertib				Owned	t		
1. Title of Derivative Security (Instr. 3)	ttle of 2. 3. Transaction Sa. Deemed Execution Date Conversion Unity or Exercise (Month/Day/Year) if any		eemed tion Date,	med 4. on Date, Transa Code (		5. Number of		6. Date Exer Expiration D (Month/Day/		cisable and	7. Title Amour Securi Underl Deriva	and nt of ties lying tive ty (Instr.	8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owners Form: Direct ( or Indir (I) (Inst	Beneficial Ownership ect (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date		Amount or Number of Shares					
Explanation	n of Respons	ses:																

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.
- 2. The shares were sold in multiple trades at prices ranging from \$60.77 to \$62.55. The price reported above reflects the weighted average sales price.
- 3. The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
- 4. The shares were sold in multiple trades at prices ranging from \$60.33 to \$61.82. The price reported above reflects the weighted average sales price.
- 5. The shares were sold in multiple trades at prices ranging from \$59.40 to \$60.50. The price reported above reflects the weighted average sales price.
- 6. The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

## Remarks:

/s/ Muthusamy Shanmugam, by attorney-in-fact Meredith

06/20/2024

W. Cook

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in	n this form are not required to respond	unless the form displays a currently valid	OMB Number.